Skip to main content
Questions about giving or our research? Call us — (800) 321-2873 Donor help Search

by
Blog
July 14, 2026

[vc_row][vc_column][vc_single_image image="69243" img_size="full" alignment="center" css=""][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=""] Glioblastoma (GBM) is the most aggressive form of brain cancer with a uniformly fatal diagnosis, limited treatment options, and a median survival of less than two years.   Although chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the treatment of certain cancers,...

, ,

by
Blog
April 24, 2025

[vc_row][vc_column][vc_single_image image="63788" img_size="full" alignment="center" css=""][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=""]In this special edition of All Things Cancer, NFCR President and CEO Dr. Sujuan Ba sits down with world-renowned cancer researcher Dr. Rakesh Jain to reflect on a career of innovation, impact, and collaboration. Dr. Jain, a longtime NFCR-supported scientist and...

, , , , ,

by
Blog
January 30, 2025

[vc_row][vc_column][vc_single_image image="63063" img_size="full" alignment="center" css=""][vc_column_text css=""]NFCR-supported researcher Dr. Rakesh K. Jain of Massachusetts General Hospital Cancer Center continues to make breakthroughs against some of the most difficult-to-treat cancers. In a recent study published in PNAS: Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma,...

, , , ,

by
Blog
April 26, 2024

[vc_row][vc_column][vc_single_image image="60558" img_size="full" alignment="center"][vc_column_text]The National Foundation for Cancer Research is thrilled to congratulate Dr. Rakesh K. Jain, the A.W. Cook Professor of Radiation Oncology (Tumor Biology) and Director of the E.L. Steele Laboratory, on his achievement of being named the 2023 Proceedings of the National...

, , , ,

by
Blog, Press Release
August 15, 2022

[vc_row][vc_column][vc_single_image image="52583" img_size="full" alignment="center"][vc_column_text] Recognized for Identifying and Overcoming Barriers in the Tumor Microenvironment To Improve Delivery and Efficacy of Anti-Cancer Medicines [/vc_column_text][vc_column_text] ROCKVILLE, MD - The National Foundation for Cancer Research (NFCR) announced today that Rakesh K. Jain, Ph.D., has been selected to receive the 2022 Szent-Györgyi...

, ,

by
Media Coverage
July 21, 2022

[vc_row][vc_column][vc_single_image image="51753" img_size="full" alignment="center" css=""][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=""]Effective and safe treatments are needed for medulloblastoma—the most common type of cancerous brain tumor in children—especially for patients whose cancer has spread to the spinal cord. A recent phase I clinical trial led by researchers at Atrium Health Levine...

, , , , ,

by
Blog
June 13, 2022

[vc_row][vc_column][vc_single_image image="50653" img_size="full" alignment="center" css=""][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=""] Did you know that normal oxygen levels inside and surrounding the tumors are critical for effective cancer treatment? Studies have found that when a tumor stays in a low oxygen status called hypoxia, it becomes resistant to many treatments. These treatments...

, ,

by
Blog
December 15, 2020

[vc_row][vc_column][vc_column_text css=""] New approach developed by Dr. Rakesh Jain and his research team identifies biomarkers that may indicate which patients will best respond to immune checkpoint blockade therapies. A research team led by NFCR-supported scientist Rakesh K. Jain, PhD, the Andrew Werk Cook Professor of Tumor Biology...

, , ,